Medical device company Flowsion reported on Friday the receipt of the CE (Conformité Européenne) Mark for its Glycostat automated glucose control system to help patients and hospitals solve the important problem of glycemic control in the intensive care unit (ICU).

Based in Denmark, the company added that the Glycostat is the only blood glucose control system to be launched in the European Union (EU) with an algorithm which enables automated blood glucose control for patients in intensive care.

This kind of technology is really crucial for intensive care medicine, where patients' lives are threatened every day. Glucose control has proven to be very difficult to perform for the intensive care units in hospitals worldwide and now getting a system that automatically helps performing blood glucose control will increase survival rate and lower treatment costs at the same time, said Hans Jorgen Pedersen.

The company has received support from The EU SME programme, which is designed to assist internationally oriented SMEs in implementing high-risk and high-potential innovation ideas.